7 recruiting, 3 completed, 2 active not recruiting, 1 not yet recruiting. 12 Phase 1, 10 Phase 2, 1 Phase 3.
Follow InxMed (Shanghai) Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FAK Inhibitor in Patients With Advanced Solid Tumors IN10028 - Advanced Solid Tumors | Phase 1 | Not yet recruiting | InxMed (Shanghai) Co., Ltd. | 75 | 2026-05-30 | 2026-05-19 |
| IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors IN10018 in combination with RNK08954 - Solid Tumor Cancer, PDAC | Phase 1 / Phase 2 | Recruiting | InxMed (Shanghai) Co., Ltd. | 92 | 2026-02-28 | 2026-02-27 |
| A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation IN10018 in combination with D-1553, anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | InxMed (Shanghai) Co., Ltd. | 400 | 2025-09-10 | 2026-03-03 |
| IN10018 Combination Therapy in Previously-treated Solid Tumors IN10018, Nab-paclitaxel, Tislelizumab - Solid Tumor | Phase 1 / Phase 2 | Withdrawn | InxMed (Shanghai) Co., Ltd. | 2025-08-13 | 2026-03-27 | |
| IN10018 Combination Therapy in Treatment-naïve ES-SCLC IN10018, Tislelizumab, Carboplatin - Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Recruiting | InxMed (Shanghai) Co., Ltd. | 120 | 2023-10-30 | 2025-04-30 |
| IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC IN10018, Furmonertinib - NSCLC | Phase 1 / Phase 2 | Recruiting | InxMed (Shanghai) Co., Ltd. | 110 | 2023-07-13 | 2025-04-30 |
| IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer IN10018, Albumin-Bound Paclitaxel, Gemcitabine - Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | InxMed (Shanghai) Co., Ltd. | 70 | 2022-12-08 | 2025-04-30 |
| Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors D-1553, IN10018 - Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | InventisBio Co., Ltd | 92 | 2022-10-12 | 2026-07-17 |
| a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors D1553, IN10018（Ifebemtinib） - Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | InxMed (Shanghai) Co., Ltd. | 140 | 2022-10-12 | 2026-07-02 |
| IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin - Ovarian Cancer Recurrent | Phase 2 | Recruiting | InxMed (Shanghai) Co., Ltd. | 168 | 2022-09-06 | 2025-04-30 |
| IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients IN10018+PLD, IN10018+PLD+Toripalimab - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Completed | InxMed (Shanghai) Co., Ltd. | 68 | 2022-03-10 | 2025-05-02 |
| IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer IN10018 in combination with PLD - Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | InxMed (Shanghai) Co., Ltd. | 150 | 2020-07-27 | 2026-05-04 |
| IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma IN10018, Docetaxel - Gastric Cancer | Phase 1 | Completed | InxMed (Shanghai) Co., Ltd. | 33 | 2020-07-09 | 2022-11-16 |
| IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma IN10018, Cobimetinib, Atezolizumab - Metastatic Melanoma | Phase 1 | Completed | InxMed (Shanghai) Co., Ltd. | 51 | 2020-03-16 | 2026-01-15 |
Carcinoma, Non-Small-Cell Lung (1) · Melanoma (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1)
1-dodecylpyridoxal (2) · tislelizumab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Docetaxel (1) · Etoposide (1) · Gemcitabine (1) · Pemetrexed (1) · Platinum (1) · aflutinib (1) · atezolizumab (1) · cobimetinib (1) · liposomal doxorubicin (1) · toripalimab (1)
China (12) · Australia (1) · United States (1)
Lingying WU (2) · Zhengbo Song (2) · Caicun Zhou (1) · Dongmei Ji (1) · Eddie Xing, Dr. (1) · Jifeng Feng (1) · Jin Li, Doctor (1) · Jun Zhao (1) · Lingying Wu (1) · Liwei Wang (1) · Shun Lu Professor, Doctor (1) · Xichun Hu (1) · Zhengbo Song Professor, Doctor (1) · Zhengbo Song, M.D (1)